Liquidia Corporation reports $51.7 million in YUTREPIA net product sales for Q3 2025
Liquidia Corporation reported net product sales of YUTREPIA totaling $51.7 million for the third quarter of 2025, marking its first full quarter of profitability since launch. Net loss for the period was $3.5 million, or $0.04 per basic and diluted share, compared to a net loss of $31.0 million, or $0.40 per share, in the same quarter of 2024. Research and development expenses decreased to $9.3 million from $11.9 million, primarily due to reduced personnel and facility costs, partially offset by higher clinical expenses for the L606 program. Total other expense, net, rose to $5.3 million from $1.8 million, mainly due to increased borrowings under the HCR Agreement. As of October 30, 2025, Liquidia received more than 2,000 unique patient prescriptions and 1,500 patient starts for YUTREPIA, supported by over 600 prescribers nationwide.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liquidia Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9566950-en) on November 03, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.